Wet Age-Related Macular Degeneration Market Expected to Grow at 7.0% CAGR

Introduction
Wet age-related macular degeneration (wet AMD) is a progressive eye disorder characterized by abnormal blood vessel growth under the macula, leading to fluid leakage, scarring, and central vision loss. It is a leading cause of blindness in individuals over the age of 60. Unlike dry AMD, which progresses more slowly, wet AMD can cause rapid vision deterioration, making timely diagnosis and treatment critical.

Over the past two decades, the introduction of anti-VEGF (vascular endothelial growth factor) therapies has revolutionized the management of wet AMD. However, the need for frequent injections, high treatment costs, and underdiagnosis remain key challenges. With innovation in biologics, biosimilars, sustained-release drug delivery, and AI-powered imaging, the wet AMD market is set for transformative growth through 2034.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72292

Market Overview
• Market Size (2024): USD 11.5 billion
• Forecast (2034): USD 22.8 billion
• CAGR (2024-2034): ~7.0%

Key Highlights:
• Increasing aging population worldwide driving AMD prevalence.
• Anti-VEGF therapies remain the gold standard, with drugs such as ranibizumab, aflibercept, and brolucizumab dominating.
• Biosimilars and sustained-release implants emerging as cost-effective and patient-friendly alternatives.
• AI and digital imaging improving screening and early detection.

Leading Players: Regeneron Pharmaceuticals, Novartis, Roche/Genentech, Bayer AG, Allergan (AbbVie), Apellis Pharmaceuticals, Kodiak Sciences, and Samsung Bioepis.
Key Drivers: Growing prevalence of AMD, therapeutic innovation, and expanded reimbursement coverage.
Key Challenges: High treatment burden, access inequalities, and long-term adherence issues.

Segmentation Analysis
By Product
• Anti-VEGF Biologics (ranibizumab, aflibercept, brolucizumab, bevacizumab)
• Biosimilars & Generics
• Sustained-Release Implants & Port Delivery Systems
• Corticosteroids & Adjunctive Therapies
• Diagnostic Imaging Tools (OCT, fundus imaging, AI platforms)
• Emerging Therapies (gene therapy, complement inhibitors)

By Platform
• Prescription Biologics
• Biosimilars
• Imaging & Diagnostic Platforms
• Clinical Trial & Research Tools

By Technology
• Intravitreal Injection Delivery
• Sustained-Release Drug Delivery (implants, refillable reservoirs)
• Optical Coherence Tomography (OCT)
• Fundus Fluorescein Angiography (FFA)
• AI-Based Screening & Monitoring Tools
• Gene Therapy Platforms

By End Use
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers
• Specialty Eye Care Centers

By Application
• Newly Diagnosed Wet AMD Patients
• Recurrent/Relapsed Cases
• Clinical Trials & Experimental Treatments

Summary: Anti-VEGF biologics remain the backbone of wet AMD treatment, but the market is shifting toward biosimilars, sustained-release implants, and digital diagnostics to reduce treatment burden and improve accessibility.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/72292/wet-macular-degeneration-market

Regional Analysis
North America
• Largest market share, driven by high AMD prevalence and strong healthcare infrastructure.
• U.S. leads in biologic adoption and reimbursement support.
• Significant clinical trial activity in sustained-release and gene therapies.
Europe
• Germany, UK, and France lead in biosimilar adoption.
• EU regulatory support for orphan drugs and advanced biologics.
• Expanding use of AI-driven retinal imaging in national screening programs.
Asia-Pacific
• Fastest-growing region, driven by aging populations in Japan, China, and India.
• Expanding infrastructure for advanced ophthalmology services.
• Rising clinical trial participation and adoption of biosimilars for affordability.
Middle East & Africa
• Gradual expansion of wet AMD diagnosis and treatment in GCC nations.
• Limited adoption in low-income African countries due to high costs.
• Growing demand for affordable biosimilars and generic imaging solutions.
Latin America
• Brazil and Mexico are the leading regional markets.
• Expanding adoption of anti-VEGF biologics in urban centers.
• Rising awareness campaigns and growth in private ophthalmology clinics.

Summary: While North America and Europe dominate, Asia-Pacific is the fastest-growing market, supported by demographics, affordability of biosimilars, and improved healthcare access.

Market Dynamics
Growth Drivers
1. Aging Populations: Increasing prevalence of AMD among elderly demographics.
2. Innovation in Therapies: Sustained-release systems and gene therapy offering long-term solutions.
3. Biosimilar Adoption: Cost-effective alternatives improving accessibility.
4. AI Imaging: Early diagnosis and monitoring reducing late-stage vision loss.

Challenges
1. High Cost of Biologics: Limiting adoption in emerging economies.
2. Frequent Injection Burden: Patients require ongoing intravitreal injections.
3. Access Inequalities: Underdiagnosis in rural and underserved regions.
4. Regulatory Complexity: Lengthy approvals for next-gen biologics and gene therapies.

Latest Trends
• Gene Therapy Research: One-time treatments showing promise in clinical trials.
• AI Screening Tools: Automated retinal imaging expanding access to early diagnosis.
• Port Delivery Systems: Devices reducing injection frequency to every 6-12 months.
• Combination Therapies: Exploring synergy between anti-VEGF and complement inhibitors.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72292

Competitor Analysis
Major Players:
• Regeneron Pharmaceuticals
• Novartis AG
• Roche/Genentech
• Bayer AG
• Allergan (AbbVie Inc.)
• Apellis Pharmaceuticals
• Kodiak Sciences Inc.
• Samsung Bioepis (biosimilars)
• Outlook Therapeutics
• Adverum Biotechnologies

Competitive Dynamics:
The wet AMD market is dominated by anti-VEGF biologics, with Regeneron and Roche/Genentech leading. However, competition is intensifying as biosimilars, sustained-release implants, and gene therapies enter the market. AI-based imaging startups are also influencing treatment pathways by enabling earlier and more precise intervention.

Conclusion
The wet AMD market is projected to grow from USD 11.5 billion in 2024 to USD 22.8 billion by 2034, at a CAGR of ~7.0%. Growth is driven by an aging population, therapeutic advances in biologics and gene therapy, and widespread adoption of imaging technologies.
Despite barriers such as high costs and treatment burden, the long-term outlook is highly positive. The next decade will bring transformative change, with innovations in sustained-release systems, biosimilars, AI diagnostics, and curative gene therapies reshaping patient outcomes.

This report is also available in the following languages : Japanese (湿性黄斑変性市場), Korean (습성 황반변성 시장), Chinese (湿性黄斑变性市场), French (Marché de la dégénérescence maculaire humide), German (Markt für feuchte Makuladegeneration), and Italian (Mercato della degenerazione maculare umida), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72292

Our More Reports:

Traumatic Brain Injury Market
https://exactitudeconsultancy.com/reports/72086/traumatic-brain-injury-market

Complex Regional Pain Syndrome Market
https://exactitudeconsultancy.com/reports/72084/complex-regional-pain-syndrome-market

West Syndrome Market
https://exactitudeconsultancy.com/reports/72082/west-syndrome-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.